Preserved adrenal function in fully PCSK9-deficient subject

International Journal of Cardiology

Volumn 176, Issue 2, 2014, Pages 499-500

  Cariou, Bertrand ^a,b,c   Benoit, Isabelle ^d   Le May, Cédric ^a  

^a L INSTITUT DU THORAX   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d District Hospital Centre   (France)

Author keywords

Genetics; PCSK9 inhibitors; Safety; Steroidogenesis

Indexed keywords

ALDOSTERONE; ANDROGEN; CORTICOTROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN;

ADRENAL FUNCTION; ADULT; ALDOSTERONE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN TEST; GENE; HORMONE RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LETTER; LOSS OF FUNCTION MUTATION; MALE; MIDDLE AGED; PCSK9 GENE; PROTEIN DEFICIENCY; PROTEIN FUNCTION; STEROIDOGENESIS; ADRENAL GLAND; DEFICIENCY; GENETICS; MUTATION; PHYSIOLOGY;

ADRENAL GLANDS; HUMANS; MALE; MIDDLE AGED; MUTATION; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84922398205     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.057     Document Type: Article

References (8)

1. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: A key modulator of cardiovascular health. Circ Res 2014; 114: 1022-36.
2. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis 2011; 216: 258-65 [2011].
3. Farnier M. PCSK9 inhibitors. Curr Opin Lipidol 2013; 24: 251-8.
4. Andersen JM, Dietschy JM. Relative importance of high and low density lipoproteins in the regulation of cholesterol synthesis in the adrenal gland, ovary, and testis of the rat. J Biol Chem 1978; 253: 9024-32.
5. Cariou B, Ouguerram K, Zaïr Y, et al. Arterioscler Thromb Vasc Biol 2009; 29: 2191-7.
6. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-offunction mutations and identification of a compound heterozygote. Am J Hum Genet 2006; 79: 514-23.
7. Hooper AJ, Marais AD, Tanyanyiwa DM, et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol levels in a Southern African population. Atherosclerosis 2007; 193: 445-8.
8. Illingworth DR, Kenny TA, Orwoll ES. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab 1982; 54: 27-33.